{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:55:21Z","timestamp":1791060921980,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RO1NS139383"],"award-info":[{"award-number":["RO1NS139383"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.tjpad.2026.100677","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:50:08Z","timestamp":1790239808000},"page":"100677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evoke (+) trials of semaglutide for early alzheimer\u2019s disease: Innovations, lessons, and implications"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey L.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-6408","authenticated-orcid":false,"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2026.100677_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(26)00459-9","article-title":"Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials","author":"Cummings","year":"2026","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100677_bib0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100677_bib0003","article-title":"Baseline characteristics from evoke and evoke+: two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease","volume":"12","author":"Scheltens","year":"2026","journal-title":"Alzheimers Dement"},{"issue":"8100","key":"10.1016\/j.tjpad.2026.100677_bib0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41586-025-10018-w","article-title":"Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias","volume":"650","author":"Zetterberg","year":"2026","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100677_bib0005","doi-asserted-by":"crossref","first-page":"7841","DOI":"10.1038\/s41598-022-11557-2","article-title":"Circulating neurofilament is linked with morbid obesity, renal function, and brain density","volume":"12","author":"Rebelos","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100677_bib0006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13195-021-00781-z","article-title":"Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease","volume":"13","author":"Grau-Rivera","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100677_bib0007","first-page":"308","article-title":"The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease","volume":"5","author":"Li","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100677_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2024.101266","article-title":"Estimands in CNS trials - a review of strategies for addressing intercurrent events","volume":"38","author":"Meszaros","year":"2024","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.tjpad.2026.100677_bib0009","article-title":"Estimating treatment effects in clinical studies of Alzheimer\u2019s disease: what are estimands and why do we need them?","author":"Mallinkcrodt","year":"2026","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100677_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3706508","article-title":"Role of c-reactive protein in diabetic inflammation","volume":"2022","author":"Stanimirovic","year":"2022","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.tjpad.2026.100677_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"11","author":"Masson","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100677_bib0012","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease","volume":"31","author":"Horie","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100677_bib0013","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100677_bib0014","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"Norgaard","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100677_bib0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's Disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100677_bib0016","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/ANNALS-24-02648","article-title":"Glucagon-like peptide-1 receptor agonists and incidence of dementia among older adults with type 2 diabetes : a target trial emulation","volume":"178","author":"Inoue","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tjpad.2026.100677_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100677_bib0018","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.tjpad.2026.100677_bib0019","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainres.2015.12.052","article-title":"The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy","volume":"1634","author":"Hansen","year":"2016","journal-title":"Brain Res"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100677_bib0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100677_bib0021","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3233\/JAD-170179","article-title":"Diabetes is not associated with Alzheimer's disease neuropathology","volume":"60","author":"Dos Santos Matioli","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100677_bib0022","article-title":"Is diabetes associated with increased pathological burden in Alzheimer's disease?","volume":"13","author":"Sadrolashrafi","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100677_bib0023","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100677_bib0024","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00415-020-09813-4","article-title":"GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis","volume":"267","author":"Malhotra","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.tjpad.2026.100677_bib0025","doi-asserted-by":"crossref","DOI":"10.1007\/s40520-025-03316-w","article-title":"Blood and imaging biomarkers of blood-brain barrier disruption in diabetic individuals with cognitive impairment","author":"Qiao","year":"2026","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100677_bib0026","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00429-020-02189-1","article-title":"Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain","volume":"226","author":"Farkas","year":"2021","journal-title":"Brain Struct Funct"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100677_bib0027","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/17425247.2024.2306138","article-title":"Blood-brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics","volume":"21","author":"Ronaldson","year":"2024","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100677_bib0028","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","article-title":"Impact of a five-dimensional framework on R&D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"10.1016\/j.tjpad.2026.100677_bib0029","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13852","article-title":"GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P\/Q-type Ca(2+) channels","volume":"6","author":"Ramracheya","year":"2018","journal-title":"Physiol Rep"},{"key":"10.1016\/j.tjpad.2026.100677_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100677_bib0031","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190888","article-title":"C-reactive protein promotes inflammation through TLR4\/NF-kappaB\/TGF-beta pathway in HL-1 cells","volume":"39","author":"Sun","year":"2019","journal-title":"Biosci Rep"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100677_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041615","article-title":"Targeting for success: demonstrating proof-of-concept with mechanistic early phase clinical pharmacology studies for disease-modification in neurodegenerative disorders","volume":"22","author":"Vissers","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100677_bib0033","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3233\/JAD-220523","article-title":"Biomarkers of Inflammation Increase with Tau and Neurodegeneration but not with Amyloid-beta in a Heterogenous Clinical Cohort","volume":"89","author":"Michopoulou","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100677_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.498056","article-title":"The mechanisms of type 2 diabetes-related white matter intensities: a review","volume":"8","author":"Sun","year":"2020","journal-title":"Front Public Health"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100677_bib0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"J Clin Exp Neuropsychol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726002001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726002001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:27:15Z","timestamp":1791059235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726002001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2274580726002001"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100677","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evoke (+) trials of semaglutide for early alzheimer\u2019s disease: Innovations, lessons, and implications","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100677"}}